title: Investigation of degradation processes in IgG1 monoclonal antibodies by limited proteolysis coupled with weak cation-exchange HPLC.
abstract: A new cation-exchange high-performance liquid chromatography (HPLC) method that separates fragment antigen-binding (Fab) and fragment crystallizable (Fc) domains generated by the limited proteolysis of monoclonal antibodies (mAbs) was developed. This assay has proven to be suitable for studying complex degradation processes involving various immunoglobulin G1 (IgG1) molecules. Assignment of covalent degradations to specific regions of mAbs was facilitated by using Lys-C and papain to generate Fab and Fc fragments with unique, protease-dependent elution times. In particular, this method was useful for characterizing protein variants formed in the presence of salt under accelerated storage conditions. Two isoforms that accumulated during storage were readily identified as Fab-related species prior to mass-spectrometric analysis. Both showed reduced biological activity likely resulting from modifications within or in proximity of the complementarity-determining regions (CDRs). Utility of this assay was further illustrated in the work to characterize light-induced degradations in mAb formulations. In this case, a previously unknown Fab-related species which populated upon light exposure was observed. This species was well resolved from unmodified Fab, allowing for direct and high-purity fractionation. Mass-spectrometric analysis subsequently identified a histidine-related degradation product associated with the CDR2 of the heavy chain. In addition, the method was applied to assess the structural organization of a noncovalent IgG1 dimer. A new species corresponding to a Fab-Fab complex was found, implying that interactions between Fab domains were responsible for dimerization. Overall, the data presented demonstrate the suitability of this cation-exchange HPLC method for studying a wide range of covalent and noncovalent degradations in IgG1 mAbs.
authors.affiliation: Department of Analytical & Formulation Sciences, Amgen Inc., 1201 Amgen Court West, Seattle, WA 98119-3105, USA.
authors.forename: Hollis
authors.initials: H
authors.lastname: Lau
authors.forename: Danielle
authors.initials: D
authors.lastname: Pace
authors.forename: Boxu
authors.initials: B
authors.lastname: Yan
authors.forename: Theresa
authors.initials: T
authors.lastname: McGrath
authors.forename: Scott
authors.initials: S
authors.lastname: Smallwood
authors.forename: Ketaki
authors.initials: K
authors.lastname: Patel
authors.forename: Jihea
authors.initials: J
authors.lastname: Park
authors.forename: Sungae S
authors.initials: SS
authors.lastname: Park
authors.forename: Ramil F
authors.initials: RF
authors.lastname: Latypov
mesh_terms: D000911:Antibodies, Monoclonal / Q000378:metabolism*; D002411:Cation Exchange Resins / Q000737:chemistry*; D002850:Chromatography, Gel; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D007074:Immunoglobulin G / Q000737:chemistry / Q000378:metabolism*; D008027:Light; D020033:Protein Isoforms / Q000378:metabolism; D055503:Protein Multimerization / Q000528:radiation effects; D011499:Protein Processing, Post-Translational / Q000528:radiation effects
chemical_list: D000911:Antibodies, Monoclonal; D002411:Cation Exchange Resins; D007074:Immunoglobulin G; D020033:Protein Isoforms